Poliovirus-specific intestinal antibody responses coincide with decline of poliovirus excretion.
The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Antibody responses to poliovirus type 3 were studied in fecal samples of 66 children immunized with 3 doses of enhanced-potency inactivated poliovirus vaccine (E-IPV), followed by 1 dose of monovalent oral poliovirus vaccine (OPV, type 3 Sabin). One fecal sample taken before OPV vaccination and 9 collected thereafter were tested for neutralizing antibodies by a microneutralization assay and for class-specific responses by heavy chain-capture radioimmunoassays. Both neutralizing antibody and IgA responses usually occurred during the second week and coincided with ceasing of virus excretion or a decrease in the excreted virus titer. Half of the vaccinees had received a trypsin-modified E-IPV, but their responses did not differ from those of children immunized with the regular E-IPV. These results are in agreement with the view that an intestinal antibody response, mainly consisting of IgA, may be involved in the ceasing of a primary poliovirus excretion.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immunization with live-attenuated vaccine mimics natural infection and results in the induction of a local secretory antibody (IgA) response that is associated with a reduction in shedding of poliovirus from the intestine [3], [4].”
From Systematic Review of Mucosal Immunity Induced by Oral and Inactivated Poliovirus Vaccines against Virus Shedding following Oral Poliovirus Challenge (2012) · cites this paper as [4]
Citations
Cites
Mucosal Immunity Induced by Enhanced-Potency Inactivated and Oral Polio Vaccines
Onorato, I. M., Modlin, J. F., McBean, A. M., Thoms, M. L., Losonsky, G. A., & Bernier, R. H. (1991) · Journal of Infectious Diseases · doi:10.1093/infdis/163.1.1 · Cited by 246
Vaccine-associated paralytic poliomyelitis. United States: 1973 through 1984
Nkowane, B. M. (1987) · JAMA · doi:10.1001/jama.257.10.1335 · Cited by 240
Minor, P. D., John, A., Ferguson, M., & Icenogle, J. P. (1986) · Journal of General Virology · doi:10.1099/0022-1317-67-4-693 · Cited by 203 · cited 1×
“Antigenic mutants demonstrated by monoclonal antibodies are known to occur in OPV recipients [23].”
BackgroundFaden, H., Modlin, J. F., Thoms, M. L., McBean, A. M., Ferdon, M. B., & Ogra, P. L. (1990) · Journal of Infectious Diseases · doi:10.1093/infdis/162.6.1291 · Cited by 178
Current status of poliovirus infections
Melnick, J. L. (1996) · Clinical Microbiology Reviews · doi:10.1128/cmr.9.3.293 · Cited by 121 · cited 1×
“The natural course of infection is best known for polioviruses, the causative agents of paralytic poliomyelitis [1].”
BackgroundVaccine-Associated Paralytic Poliomyelitis
Beausoleil, J. L., Nordgren, R. E., & Modlin, J. F. (1994) · Journal of Child Neurology · doi:10.1177/088307389400900324 · Cited by 108
Viral Vaccination Via the Mucosal Routes
Ogra, P. L. O., Fishaut, M., & Gallagher, M. R. (1980) · Clinical Infectious Diseases · doi:10.1093/clinids/2.3.352 · Cited by 106
Pipkin, P. A., Wood, D. J., Racaniello, V. R., & Minor, P. D. (1993) · Journal of Virological Methods · doi:10.1016/0166-0934(93)90022-j · Cited by 105
Modlin, J. F., Halsey, N. A., Thoms, M. L., Meschievitz, C. K., Patriarca, P. A., & the Baltimore Area Polio Vaccine Study Group (1997) · Journal of Infectious Diseases · doi:10.1093/infdis/175.supplement_1.s228 · Cited by 93
Fricks, C. E., Icenogle, J. P., & Hogle, J. M. (1985) · Journal of Virology · doi:10.1128/jvi.54.3.856-859.1985 · Cited by 70 · cited 1×
“treating the immunogen with trypsin that selectively cleaves the BC-loop [15, 16].”
BackgroundZhaori, G., Sun, M., & Ogra, P. L. (1988) · Journal of Infectious Diseases · doi:10.1093/infdis/158.1.160 · Cited by 59 · cited 1×
“00 fection [3, 6], even with the modern enhanced-potency preparations (E-IPV) [7–11].”
BackgroundSecretory and Serum Immunoglobulin Class-Specific Antibodies to Poliovirus After Vaccination
Carlsson, B., Zaman, S., Mellander, L., Jalil, F., & Hanson, L. A. (1985) · Journal of Infectious Diseases · doi:10.1093/infdis/152.6.1238 · Cited by 53 · cited 1×
“00 fection [3, 6], even with the modern enhanced-potency preparations (E-IPV) [7–11].”
BackgroundRoivainen, M., & Hovi, T. (1987) · Journal of Virology · doi:10.1128/jvi.61.12.3749-3753.1987 · Cited by 48
Self-citationZhaori, G., Sun, M., Faden, H. S., & Ogra, P. L. (1989) · Journal of Infectious Diseases · doi:10.1093/infdis/159.6.1018 · Cited by 42
Cleavage of VP1 and modification of antigenic site 1 of type 2 polioviruses by intestinal trypsin
Roivainen, M., & Hovi, T. (1988) · Journal of Virology · doi:10.1128/jvi.62.9.3536-3539.1988 · Cited by 34 · cited 1×
“The antigenic site distribution of antibody specificities induced by IPV is different from those seen after OPV or natural immunizations, especially as regards poliovirus type 3 (PV3) [12–14].”
BackgroundSelf-citationComparative Evaluation of Immunization with Live Attenuated and Inactivated Poliovirus Vaccines
Ogra, P. L. O. (1995) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1995.tb44442.x · Cited by 26 · cited 1×
“The antigenic site distribution of antibody specificities induced by IPV is different from those seen after OPV or natural immunizations, especially as regards poliovirus type 3 (PV3) [12–14].”
BackgroundHovi, T., Väisänen-Rhen, V., Ukkonen, P., & von Bonsdorff, C. (1982) · Journal of Virological Methods · doi:10.1016/0166-0934(82)90096-9 · Cited by 23 · cited 1×
“This is most likely due to the abundant proteases in stools [22], not completely inhibited by the FCS added into the extracts for this purpose.”
BackgroundSelf-citationRoivainen, M., Montagnon, B., Chalumeau, H. P., Murray, M. G., Wimmer, E., & Hovi, T. (1990) · Journal of Virology · doi:10.1128/jvi.64.2.559-562.1990 · Cited by 21
Self-citationFecal IgA Antibody Responses after Oral Poliovirus Vaccination in Infants and Elder Children
Nishio, O., Sumi, J., Sakae, K., Ishihara, Y., Isomura, S., & Inouye, S. (1990) · Microbiology and Immunology · doi:10.1111/j.1348-0421.1990.tb01044.x · Cited by 19 · cited 1×
“Several observations from previous studies suggest that an intestinal antibody response may have a role in intestinal resistance to reinfection by poliovirus [3, 4].”
Piirainen, L., Stenvik, M., Roivainen, M., Eskola, J., Beuvery, E. C., & Hovi, T. (1999) · Vaccine · doi:10.1016/s0264-410x(98)00325-9 · Cited by 19 · cited 6×
“The vaccine groups showed, however, no significant difference in the intestinal immunity as judged by the length and amount of excreted challenge virus [18].”
BackgroundMethodResultInfluentialSelf-citationSTUDIES ON POLIOVIRUS COPROANTIBODY
Kawakami, K., Tatsumi, H., Tatsumi, M., & Kono, R. (1966) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a120557 · Cited by 17
Immunogenicity of Trypsin treated Type 2 and Type 3 Poliovirus in Rats
Kersten, G. F. A., Lantinga, M., Hazendonk, T. G., & Beuvery, E. C. (1995) · Biologicals · doi:10.1006/biol.1995.0029 · Cited by 9 · cited 1×
“NT antibodies were measured by a modification of the standard microneutralization assay [20].”
MethodRoivainen, M., Piirainen, L., & Hovi, T. (1993) · Vaccine · doi:10.1016/0264-410x(93)90254-u · Cited by 9 · cited 1×
“[21].”
Self-citationImmunogenicity of a pilot inactivated poliovirus vaccine with trypsin-treated type 3-component
Piirainen, L., Roivainen, M., Litmanen, L., Eskola, J., Beuvery, E. C., & Hovi, T. (1997) · Vaccine · doi:10.1016/s0264-410x(96)00119-3 · Cited by 8
Self-citation
Cited by
Simek, M. D., Rida, W., Priddy, F. H., Pung, P., Carrow, E., Laufer, D. S., Lehrman, J. K., Boaz, M., Tarragona-Fiol, T., Miiro, G., et al. (2009) · Journal of Virology · doi:10.1128/jvi.00110-09 · Cited by 594
Hird, T. R., & Grassly, N. C. (2012) · PLoS Pathogens · doi:10.1371/journal.ppat.1002599 · Cited by 221
Expert Review on Poliovirus Immunity and Transmission
Duintjer Tebbens, R. J., Pallansch, M. A., Chumakov, K. M., Halsey, N. A., Hovi, T., Minor, P. D., Modlin, J. F., Patriarca, P. A., Sutter, R. W., Wright, P. F., et al. (2013) · Risk Analysis · doi:10.1111/j.1539-6924.2012.01864.x · Cited by 109
“Grading Table of the Evidence for Average Time Until the Last Positive Stool Specimen and Proportions with Fecal Excretion Over Time from Monovalent OPV Challenge Studies with at Least Two Stool Specimen Collection Times Number of Included Studies(refs)a from Which We Could Extract Proportion Excreting as Average Time…”
MethodSelf-citationNorton, E. B., Bauer, D. L., Weldon, W. C., Oberste, M. S., Lawson, L. B., & Clements, J. D. (2015) · Vaccine · doi:10.1016/j.vaccine.2015.02.069 · Cited by 76
Pliaka, V., Kyriakopoulou, Z., & Markoulatos, P. (2012) · Expert Review of Vaccines · doi:10.1586/erv.12.28 · Cited by 85
Metadata
- Authors
- Valtanen, S., Roivainen, M., Piirainen, L., Stenvik, M., & Hovi, T.
- Corresponding author
- Hovi, Tapani
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2000-07
- Volume
- 182
- Issue
- 1
- Pages
- 1-5
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2115558992
- Cited by
- 36
- References
- 24
- Citations by year
- 2024: 1 · 2023: 2 · 2022: 1 · 2021: 3 · 2020: 2 · 2017: 2 · 2015: 1 · 2014: 3 · 2013: 1 · 2012: 6
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Infectious Diseases (publishedVersion)
- PubMed (publishedVersion)
- STM:n Hallinnonalan avoin julkaisuarkisto (Julkari) (submittedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Viral Infections and Immunology Research
- Health Sciences › Medicine › Epidemiology › Virology and Viral Diseases
- Health Sciences › Medicine › Infectious Diseases › Viral gastroenteritis research and epidemiology
- Keywords
- poliovirus type 3, IgA, neutralizing antibodies, oral polio vaccine, inactivated poliovirus vaccine, children, microneutralization
- MeSH terms
- Feces, Humans, Immunoglobulin A, Secretory, Immunoglobulin G, Immunoglobulin M, Infant, Intestines, Poliovirus Vaccine, Inactivated, Poliovirus, Viral Load
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.